Neovascular Age-related Macular Degeneration(nAMD)

36 clinical trials · Condition

Sort:Newest first Oldest first

◉ Watch Neovascular Age-related Macular Degeneration(nAMD)

Record	Firm	Date
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit (NCT05282004)	Sandoz	2022-05-16
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe (NCT05161806)	Sandoz	2022-03-11
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) (NCT05269966)	Novartis Pharmaceuticals	2022-03-09
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD (NCT05210803)	AbbVie	2021-12-20
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) (NCT04657289)	Hoffmann-La Roche	2021-07-14
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal (NCT04764656)	Novartis Pharmaceuticals	2021-05-10
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (NCT04746963)	AsclepiX Therapeutics, Inc.	2021-02-01
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema (NCT04543331)	Novartis Pharmaceuticals	2020-11-05
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NCT04514653)	AbbVie	2020-08-25

Track Neovascular Age-related Macular Degeneration(nAMD) automatically

Every clearance here is in the API, with alerts when new ones post.